

TABLE 1.

Sponsor	NADA Number, Product (Drug)	21 CFR Section Affected, (Sponsor Drug Labeler Code)
Abbott Laboratories, North Chicago, IL 60064	NADA 99-568, FURANACE Caps (nifurpirinol)	529.1526 (000074)
Biocraft Laboratories, Inc., 92 Route 46, Elmwood Park, NJ 07407	NADA 140-889, DERM-OTIC Ointment (neomycin sulfate, nystatin, thioestrepton, triamcinolone acetonide)	524.1600a (000332)
First Priority, Inc., 1585 Todd Farm Dr., Elgin, IL 60123	NADA 48-646, THERAZONE Injection (phenylbutazone)	522.1720 (058829)
Happy Jack, Inc., Snow Hill, NC 28580	NADA 121-556, Selenium Sulfide Suspension (selenium disulfide) NADA 121-723, Nitrofurazone Dressing NADA 125-137, FILARICIDE Capsules (diethylcarbamazine citrate)	524.2101 (023851) 524.1580b (023851) 520.622d (023851)
IMPAX Laboratories, Inc., 30831 Huntwood Ave., Hayward, CA 94544	NADA 92-151, N-Butyl Chloride Canine Worming Caps NADA 65-065, Tetracycline HCl Caps NADA 138-900, Dichlorophene/Toluene	520.260 (000115) 520.2345a (000115) 520.580 (000115)
Jorgensen Laboratories, Inc., 1450 North Van Buren Ave., Loveland, CO 80538	NADA 10-481, SUREJETS (salicylic acid)	529.2090 (048087)
Pliva d.d., Ulica grada Vukovara 49, 10000 Zagreb, Croatia	ANADA, 200-232, GEOMYCIN 200 Injection (oxytetracycline)	522.1660a (011722)
Purina Mills, Inc., P.O. Box 66812, St. Louis, MO 63166-6812	NADA 65-113 AUREO Sulfa Soluble Powder (chlortetracycline/sulfamethazine)	N/A (017800)
Roche Vitamins, Inc., 45 Waterview Blvd., Parsippany, NJ 07054-1298	NADA 140-848, VETEEZE Injection (diazepam)	522.575 (063238)
Teva Pharmaceuticals USA, 650 Cathill Rd., Sellersville, PA 18960	NADA 131-806, Furosemide Tablets	520.1010 (000093)
Virbac AH, Inc., 3200 Meacham Blvd., Ft. Worth, TX 76137	NADA 10-886, Purina Liquid Wormer (piperazine citrate)	N/A (051311)
Wyeth Laboratories, Division of American Home Products Corp., P.O. Box 8299, Philadelphia, PA 19101	NADA 10-782, SPARINE Injection (promazine) NADA 55-008, BICILLIN Fortified (penicillin G benzathine and penicillin G procaine)	522.1962 (000008) 522.1696a (000008)

Therefore, under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10), redelegated to the Center for Veterinary Medicine (21 CFR 5.84), and in accordance with § 514.115 *Withdrawal of approval of applications* (21 CFR 514.115), notice is given that approval of NADAs 10-481, 10-782, 10-886, 48-646, 55-008, 65-065, 65-113, 99-568, 121-556, 121-723, 125-137, 131-806, 138-900, 140-848, 140-889, and ANADA 200-232, and all supplements and amendments thereto, is hereby withdrawn, effective September 6, 2005.

In a final rule published elsewhere in this issue of the **Federal Register**, FDA is amending the animal drug regulations to reflect the withdrawal of approval of these NADAs.

Dated: July 5, 2005.

Linda Tollefson,

Acting Director, Center for Veterinary Medicine.

[FR Doc. 05-16994 Filed 8-25-05; 8:45 am]

BILLING CODE 4160-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Notice of Establishment

Pursuant to the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), the Director, National Institutes of Health (NIH), announces the establishment of the National Commission on Digestive Diseases (Commission).

This Commission shall conduct an overview of the state-of-the-science in

the field of digestive diseases research and develop a long-range plan for digestive diseases research consistent with the research mission of NIH. The overall plan will focus on the goal of improving the health of the nation through digestive diseases research and will include specific objectives and goals and a recommended time line for their implementation. Recommendations shall be made to the Director, NIH and to Congress.

The Commission shall be composed of 16 members appointed by the Director, NIH and 18 nonvoting ex officio members. Of the appointed members, who shall have a broad diversity of scientific and professional experience, 12 shall be knowledgeable about digestive diseases as members of academic or medical research and practice communities involved in digestive diseases research, including

individuals in allied health specialties relevant to digestive diseases research. Four members shall be appointed who have close personal or family experience with digestive diseases or experience with patient-oriented organizations in digestive diseases.

Unless renewed by appropriate action prior to its expiration, the Charter for the National Commission on Digestive Diseases will expire two years from the date of establishment.

Dated: August 16, 2005.

Elias A. Zerhouni,

Director, National Institutes of Health.

[FR Doc. 05-17012 Filed 8-25-05; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director, National Institutes of Health; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Advisory Committee to the Director, NIH.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Advisory Committee to the Director, NIH.

Date: September 6, 2005.

Time: 11 a.m. to 12 p.m.

Place: National Institutes of Health, Building 31, 31 Center Drive, Room 5B64, Bethesda, MD 20892.

Agenda: To review and evaluate grant applications (Telephone Conference Call).

Contact Person: Shelly Pollard, ACD Coordinator, National Institutes of Health, 9000 Rockville Pike, Building 31, Room 5B64, Bethesda, MD 20892, 301-496-0959.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Dated: August 19, 2005.

Anthony M. Coelho, Jr.,

Acting Director, Office of Federal Advisory Committee Policy.

[FR Doc. 05-17016 Filed 8-25-05; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the meeting of the National Cancer Advisory Board.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

A portion of the meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4), and 552b(c)(6), as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Advisory Board.

Open: September 20, 2005, 8 a.m. to 4:15 p.m.

Agenda: Program reports and presentations; Business of the Board.

Place: National Cancer Institute, 9000 Rockville Pike, Building 31, C Wing, 6th Floor, Conference Room 10, Bethesda, MD 20892.

Contact Person: Dr. Paulette S. Gray, Executive Secretary, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, 8th Floor, Room 8001, Bethesda, MD 20892-8327, (301) 496-5147.

Name of Committee: National Cancer Advisory Board.

Closed: September 20, 2005, 4:15 p.m. to Adjournment.

Agenda: Review of grant applications.

Contact Person: Dr. Paulette S. Gray, Executive Secretary, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, 8th Floor, Room 8001, Bethesda, MD 20892-8327, (301) 496-5147.

Name of Committee: National Cancer Advisory Board.

Open: September 21, 2005, 8 a.m. to 12 p.m.

Agenda: Program reports and presentations; Business of the Board.

Contact Person: Dr. Paulette S. Gray, Executive Secretary, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, 8th Floor, Room 8001, Bethesda, MD 20892-8327, (301) 496-5147.

Any interested person may file written comments with the committee by forwarding the statement to the Contact person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's Home page: deainfo.nci.nih.gov/advisory/ncab.htm, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS.)

Dated: August 18, 2005.

Anthony M. Coelho, Jr.,

Acting Director, Office of Federal Advisory Committee Policy.

[FR Doc. 05-17011 Filed 8-25-05; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center for Complementary & Alternative Medicine; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Center for Complementary and Alternative Medicine Special Emphasis Panel Basic Science.

Date: October 17-18, 2005.

Time: 8 a.m. to 3 p.m.

Agenda: To review and evaluate grant applications.